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According to the literature, isolated rib metastasis from
prostate cancer (PCa) is extremely rare and the utility of
metastasectomy for its treatment warrants investigation.
Here, we present a case of adenocarcinoma of the prostate
with synchronous isolated left sixth rib metastasis, which
was treated with metastasectomy, androgen deprivationby Elsevier Taiwan LLC. This is an open access article under the
/4.0/).
Downstaging of bony metastatic prostate cancer 71therapy (ADT), and subsequent radical prostatectomy. The
treatment and prognosis of the case are discussed.2. Case Report
A 68-year-old man, apparently healthy, underwent trans-
rectal ultrasound-guided prostate biopsy in July 2013
because of an elevated prostate-specific antigen (PSA) level
(40.12 ng/mL) observed during a health examination. A
histopathological examination confirmed adenocarcinoma
of the prostate, with a Gleason Score of 3 þ 3. Magnetic
resonance imaging of the prostate revealed a tumor located
at the right posterior lobe of the prostate with capsular
invasion (Figure 1). Staging whole-body bone scintigraphy
showed isolated radiotracer uptake at the lateral aspect of
the left sixth rib (Figure 2). Because the lesion was isolated
and distant from the prostate, a wide excision was per-
formed, and a histopathological examination confirmed it
to be a metastatic adenocarcinoma of prostatic origin, with
a Gleason Score of 4 þ 4 (Figures 3 and 4).
After surgery, the patient received ADT containing
luteinizing hormone-releasing hormone agonists and anti-
androgen. The serum PSA level decreased and became
undetectable in October 2013. Follow-up bone scintigraphy
in January 2014 and May 2014 showed no new and abnormal
radiotracer uptake. Pelvis magnetic resonance imaging in
May 2014 revealed a residual tumor with shrinkage.
Therefore, we performed salvage robot-assisted radical
prostatectomy and bilateral pelvic lymph node dissection.
A permanent pathology section showed complete remission
of the primary tumor, with no evidence of regional lymph
node involvement. Recent follow-up serum PSAFigure 1 Magnetic resonance imaging of the prostate: an
axial T2-weighted image showing low signal intensity (white
arrowhead).measurements and scans showed no evidence of tumor
recurrence at either the primary or the metastatic site thus
far.3. Discussion
Bone is the most common site of PCa metastasis, with 3% of
PCa cases presenting with bone metastasis at diagnosis.1
Most metastatic bony lesions are found in the vertebrae
and pelvis, followed by extremely rare instances of isolated
rib metastasis from PCa; only 1.2% of metastatic costal
lesions do not metastasize to the vertebrae.2
Patients with skeletal metastasis from PCa show 1- and
5-year survival rates of 47% and 3%, respectively1; half of
these patients may die within 30e35 months after diag-
nosis.2 A lesser extent of bony involvement on bone scans
correlates with more favorable survival.3e5 In other words,
efficient control of distant metastasis can theoretically
improve the treatment outcome.
ADT is the gold standard for treating metastatic PCa.
Most metastatic PCa cases initially respond to ADT; how-
ever, most of them ultimately adapt and develop resistance
to the therapy, causing a loss of disease control and even-
tually death. Metastasectomy for isolated pulmonary or
adrenal metastasis from PCa has been reported in the past,
and some cases have shown favorable outcomes after the
complete resection of metastatic lesions.6,7 Therefore, in
cases of rare isolated bone metastasis from PCa, the effi-
ciency of an early and aggressive metastasectomy must be
determined.
In our case, the bone metastasis was unusual because it
was isolated to a single rib during the diagnosis of PCa.
Because the patient had favorable general performance
(Eastern Cooperative Oncology Group performance
score Z 0) and without comorbidities, combined meta-
stasectomy and ADT were performed initially for efficient
distant control. Both PSA levels and serial bone scans
showed no evidence of recurrence postoperatively.
Definite local therapy (radical prostatectomy or
brachytherapy) of the primary tumor in men with meta-
static PCa can improve their survival.8,9 Based on this
rationale, we performed radical prostatectomy and bilat-
eral pelvic lymph node dissection in our case, followed by
metastasectomy and ADT. Thus far, our case remains can-
cer free.
Because of the oligometastatic statedan intermediate
state between local disease and widespread meta-
stasesdthe optimal timing of administering ADT cannot be
decided. The Current European Association of Urology
guidelines suggest postponing ADT in well-informed
asymptomatic metastatic patients because of the lack of
clear survival benefits and ADT-associated negative effects.
Nonetheless, we administered ADT to our patient as neo-
adjuvant hormonal therapy because we intended to in-
crease tumor resectability, monitor tumor behavior during
treatment, and eradicate possible micrometastatic foci. In
men responding well to neoadjuvant ADT, Heidenreich
et al10 demonstrated that cytoreductive prostatectomy for
PCa and low-volume skeletal metastases considerably
increased the rates of clinical progression-free and cancer-
specific survival rates.
Figure 2 Bone scans showing solitary and intense uptake of the Tc-99m tracer to lateral aspect of the left sixth rib.
Figure 3 Hematoxylin and eosin-stained biopsy specimen of
the left sixth rib showing cribriform adenocarcinoma with nu-
clear hyperchromatism tissue.
Figure 4 Immunostained biopsy specimen of the left sixth
rib, which is positive for prostate-specific antigen.
72 H.-K. Ting et al.Because of its rarity in the literature, the appropriate
treatment plan for isolated metastatic PCa is not well
established. However, in a specific subset of patients with
resectable isolated metastasis, such as our case, meta-
stasectomy may be a promising option.References
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